ILKOS Therapeutic
Oral compound developer for venous lower limb ulcers
About ILKOS Therapeutic
ILKOS Therapeutic Inc. was a clinical-stage biopharmaceutical company focused on developing an oral treatment for venous lower limb ulcers. Founded in 2016 and based in Laval, Quebec, the company's primary objective was to address this condition, which predominantly affects older individuals.
The company was established through a significant $21 million seed investment, a record-breaking amount for a Canadian life sciences startup at the time. This funding was a collaborative effort between CTI Life Sciences Fund, Fonds de solidarité FTQ, and Servier Canada, with each contributing $7 million. This strategic collaboration between a venture capital fund, an institutional investor, and a global corporate investor enabled the substantial seed round.
ILKOS Therapeutic's core asset was the clinical-stage compound S42909, for which it obtained an exclusive worldwide license from Laboratoires Servier. The compound had demonstrated promising wound-healing properties in preclinical trials and had been proven safe in Phase 1 clinical trials involving over 300 healthy volunteers. The company's mission was to advance S42909 by demonstrating its efficacy and safety through a Phase 2a multicenter trial in North America and Europe. The ultimate goal was to offer the first disease-modifying oral treatment for a condition affecting 1% to 1.5% of the population.
In December 2020, ILKOS Therapeutic Inc. was acquired by Odan Laboratories Ltd., a Canadian pharmaceutical company. The acquisition marked an expansion and diversification of Odan's research and development activities. Following the acquisition, ILKOS is considered a deadpooled or inactive company.
Source: Dealroom company dataNews
Open roles
ILKOS Therapeutic in the Quebec City ecosystem
The ILKOS Therapeutic office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Fonds de solidarité FTQ
CTI Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ILKOS Therapeutic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ILKOS Therapeutic on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.